trending Market Intelligence /marketintelligence/en/news-insights/trending/U_O8s-_aVPOnHbTa2kFVBg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Summit Therapeutics names COO

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Summit Therapeutics names COO

Summit Therapeutics PLC appointed David Roblin COO and president of research and development.

Roblin will lead research and development and commercial functions to support the development of the company's Duchenne muscular dystrophy and C. difficile infection programs. Roblin, who has been acting as a research and development adviser to Summit since 2014, will assume his new role on an interim basis in April, and become permanent in June.

He was most recently COO and director of scientific translation at the Francis Crick Institute, a London-based biomedical institute.